ClinicalTrials.gg
RecruitingNCT07432737Updated Feb 27, 2026

One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

An interventional study of Tranexamic acid in Hip Fractures, sponsored by University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje. Recruiting at 1 site in North Macedonia. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing Tranexamic Acid in Hip Fractures — 2 open to participants now, 3 under way, none of them phase 3. Tranexamic Acid · Hip Fractures.

Planned enrollment
10th of 21
120 · median 120
Started
2026
the only one that year
No phase
6 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies testing Tranexamic Acid in Hip Fractures, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, and was the 22nd registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

2 of the 22 studies testing Tranexamic Acid in Hip Fractures are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Tranexamic Acid

Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing Tranexamic Acid in Hip Fractures, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether giving one dose or two doses of tranexamic acid can safely lower blood loss in older adults having surgery for certain hip fractures. The study includes adults aged 65 years or older who need surgery for pertrochanteric or subtrochanteric hip fractures.

The main questions the study aims to answer are:

  • Does giving two doses of tranexamic acid lower the need for blood transfusions compared to one dose?
  • Does tranexamic acid help keep hemoglobin levels higher after surgery?
  • Is tranexamic acid safe in this group of participants? Researchers will compare participants who receive one dose of tranexamic acid with those who receive two doses to see which approach works better and is safe.

Participants will:

  • Receive either one dose of tranexamic acid before surgery or two doses, one before and one after surgery
  • Have standard surgery to fix their hip fracture within 48 hours of hospital admission
  • Be monitored during their hospital stay for blood loss, transfusions, and medical problems
  • Be followed for up to 90 days after surgery to check for safety A total of 120 participants will take part in this study, which is being conducted at the University Clinic "St. Naum Ohridski" in Skopje, North Macedonia.
Read the detailed description

This prospective, randomized,single-center clinical study is conducted at the University Clinic for Surgical Diseases "St. Naum Ohridski." Adults aged 65 years or older with pertrochanteric or subtrochanteric femoral fractures are eligible. All patients undergo surgery within 48 hours of admission, according to current recommendations for treatment of pertrochanteric and subtrochanteric fractures. Fractures are classified according to the AO/OTA system by at least two trauma surgeons; discrepancies are resolved by discussion.

Routine preoperative evaluation is performed according to institutional standards and may include patient history, physical examination, standard imaging (X-ray of the pelvis and affected hip, with additional CT scans if indicated), laboratory tests including complete blood count, biochemistry, and coagulation tests, as well as anesthesia assessment. Relevant comorbidities and chronic medications are recorded.

Eligible participants are randomly assigned to one of two treatment groups. One group receives a single prophylactic dose of tranexamic acid, while the other receives two doses according to the study protocol. All participants receive standard surgical and anesthetic care in accordance with institutional practice.

Surgical Procedure:

Surgery is performed under spinal or general anesthesia. Stable pertrochanteric fractures are treated with DHS or short intramedullary nail. Unstable pertrochanteric and subtrochanteric fractures are treated with intramedullary nailing. Reduction may be open or closed, with fluoroscopic guidance. Wound closure is standard; drain placement is at surgeon discretion.

Blood Loss Measurement:

Intraoperative visible blood loss (VBLop) is calculated as suction volume minus irrigation fluids plus blood in sponges, visually estimated.Total visible blood loss (VBL) is the sum of VBLop and drain output. Total blood loss (TBL) is calculated using standard formulas based on preoperative and postoperative hematocrit and red blood cell transfusions. Blood volume is calculated using standard formulas. Hidden blood loss (HBL) is calculated as total blood loss minus visible blood loss (TBL minus VBL).

Red blood cell transfusions are given if hemoglobin is less than 8 grams per deciliter or if symptomatic anemia occurs.

Postoperative Monitoring:

Laboratory tests (Hb, Hct, urea, creatinine, electrolytes) are measured 6 hours postoperatively, then daily up to day 3, or longer if clinically indicated.. Blood products administered per clinical indication. Early mobilization usually on post-op day 1-2. Intensive care unitstay and total hospitalization recorded.

All patients will receive antibiotic prophylaxis according to the institutional protocol. Thromboprophylaxis will be administered using a combined approach, including pharmacologic measures (enoxaparin or an oral anticoagulant if indicated) and mechanical measures (high-compression stockings until full mobilization). Adverse events and complications will be monitored and documented during hospitalization and up to 90 days postoperatively. Routine postoperative assessments, including clinical examination, laboratory tests, and radiographic imaging, will follow standard clinical practice. Additional diagnostic procedures, such as ECG, biochemical markers, Doppler ultrasound, or radiography, will be performed as clinically indicated by the operating surgeon, on-call physician, anesthesiologist, internist, or other relevant specialists, based on the patient's condition. Major adverse events include cerebrovascular events, myocardial infarction, pulmonary embolism, deep vein thrombosis, bowel ischemia, and convulsions. Minor events include nausea, vomiting, headache, and abdominal pain. Surgical complications encompass reoperation for bleeding, hematoma, wound infection, wound healing issues, implant problems (cut-out or malposition), delayed union, malunion, and avascular necrosis. General complications include pneumonia, urinary tract infection, renal insufficiency, drug allergy, and decubitus ulcers. Mortality will be recorded at 30 and 90 days postoperatively.

Patients are followed with outpatient visits at 14 days, 1 month, 2 months, 3 months. Clinical and radiographic evaluation. All complications and adverse events documented.

Data are entered into a secure, anonymized electronic database with predefined variables, units, and normal ranges.Range and consistency checks are performed to ensure data validity.All preoperative, intraoperative, and postoperative data are verified against medical records.Missing or unavailable data are documented and handled according to standard statistical practices. Standard clinical procedures are followed for patient recruitment, data collection, adverse event monitoring, and reporting.

Sample Size: A total of 120 participants (60 per group) are enrolled, sufficient to detect clinically meaningful differences in blood loss and transfusion requirements.

Statistical Analysis Data analysis will be performed using SPSS software (version 25.0; IBM, SPSS, USA). Normality of data distribution will be assessed using the Kolmogorov-Smirnov and Shapiro-Wilk tests.

Categorical (nominal) variables will be presented as counts and percentages. Continuous (quantitative) variables will be presented as mean ± standard deviation, minimum and maximum values, median, and interquartile range.Comparisons between the single-dose and two-dose tranexamic acid groups will be performed as follows: categorical variables- Chi-square test or Fisher exact test, as appropriate, continuous variables (independent samples)- Student's t-test or Mann-Whitney test, depending on data distribution, repeated measures / paired data-Student's t-test for dependent samples, Wilcoxon matched-pairs test, repeated measures ANOVA, or Friedman ANOVA, as appropriate.

Subgroup analyses will be performed according to the type of osteosynthesis (dynamic hip screw or intramedullary fixation) and dosing group for all evaluated outcomes, including incidence of allogeneic transfusion, hemoglobin drop, total and hidden blood loss, total transfused blood volume, length of hospital stay, thrombotic events, and mortality.

Statistical significance will be defined at p less than 0.05.

03

Conditions studied

  • Hip Fractures

Keywords

  • tranexamic acid
  • blood loss
  • blood transfusion
  • safety
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained
  • Patients aged 65 years or older
  • Patients with pertrochanteric femoral fracture (AO/OTA classification: 31A1.2, 31A1.3, 31A2, 31A3) or subtrochanteric femoral fracture (AO/OTA classification: 32; fractures from the level of the lesser trochanter to 5 cm distally)
  • Surgical treatment performed within 48 hours of hospital admission

Exclusion criteria

Exclusion Criteria:

  • Age younger than 65 years
  • Known allergy or to tranexamic acid
  • Active thromboembolic event (deep vein thrombosis, arterial thrombosis, pulmonary embolism) or history of vascular event within the past year (myocardial infarction, coronary or peripheral vascular stenting, thromboembolism, stroke)
  • Impaired renal function defined as serum creatinine >120 µmol/L in the last preoperative laboratory test
  • History of malignant disease
  • History of seizure disorder or chronic anticonvulsant therapy
  • Polytrauma or multiple trauma
  • More than one fracture
  • Previous fracture of the same hip
  • Preoperative level \<8 g/dL (last laboratory test before surgery)
  • Thrombocytopenia or other coagulation disorders
  • Treatment with vitamin K antagonists with >1.5
  • Treatment with low-molecular-weight heparins without appropriate preoperative discontinuation according to clinical protocol (usually ≥24 hours for prophylactic doses and ≥24-36 hours for therapeutic doses)
  • Treatment with direct oral anticoagulants without appropriate preoperative discontinuation (usually 24-48 hours, depending on renal function and bleeding risk)
  • Treatment with P2Y12 inhibitors (e.g., ticagrelor, clopidogrel, prasugrel) when, according to anesthesiologist assessment, surgery cannot be safely performed within 48 hours
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Group A: Single-Dose TXA

    Patients will receive a single intravenous dose of 15 mg/kg Tranexamic Acid 10-20 minutes before the surgical incision, followed by a placebo(saline solution) 3 hours later.

    Drug: Tranexamic acid

  • Experimental
    Group B: Two-Dose TXA

    Patients will receive a 15 mg/kg intravenous dose of Tranexamic acid 10-20 minutes before the surgical incision and a second intravenous dose of 15 mg/kg Tranexamic Acid 3 hours after the first dose

    Drug: Tranexamic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of allogeneic blood transfusion

    Comparison of the incidence of intraoperative and postoperative allogeneic transfusions (≥1 unit of red blood cells) between patients receiving a single intravenous dose of tranexamic acid (15 mg/kg, pre-incision) and those receiving two doses (15 mg/kg pre-incision + 15 mg/kg 3 hours after the first dose).

    Time frame: From start of surgery through postoperative day 5.

Secondary outcomes

  1. Hemoglobin drop

    Comparison of the hemoglobin decrease between participants receiving a single dose versus those receiving two doses of tranexamic acid, measured preoperatively and on postoperative days 1, 2, and 3

    Time frame: Preoperative to postoperative day 3

  2. Total and hidden blood loss

    Comparison of total and hidden blood loss between single-dose and two-dose groups.

    Time frame: From start of surgery through postoperative day 3

  3. Volume of transfused blood products

    Comparison of total volume of transfused blood products (fresh frozen plasma, platelet concentrates) between groups.

    Time frame: From start of surgery through postoperative day 5.

  4. Length of hospital stay

    Comparison of duration of hospitalization in days between groups.

    Time frame: From surgery through hospital discharge up to 30 days postoperatively

  5. Incidence of thrombotic events

    Comparison of thrombotic events (deep vein thrombosis, pulmonary embolism, cerebrovascular event, myocardial infarction, postoperative bowel ischemia) during hospitalization and up to 90 days postoperatively.

    Time frame: Up to 90 days postoperatively

  6. Mortality

    Comparison of 30-day and 90-day mortality between groups.

    Time frame: 30 and 90 days postoperatively

  7. Subgroup analysis by osteosynthesis type

    Subgroup comparison according to type of osteosynthesis (DHS or intramedullary fixation) for all analyzed parameters-incidence of allogeneic transfusion, hemoglobin decrease, total and hidden blood loss, volume of transfused blood products, length of hospitalization, thrombotic events, and mortality-between participants receiving a single dose versus those receiving two doses of tranexamic acid.

    Time frame: From preoperative baseline up to 90 days postoperatively

07

Study locations

1 of 1 sites recruiting
  • University Clinic PHI University Clinic for Surgical Diseases, St. Naum Ohridski
    Skopje, 1000, North Macedonia
    Recruiting
08

References and documents

Publications

  • Mercuriali F, Inghilleri G. Proposal of an algorithm to help the choice of the best transfusion strategy. Curr Med Res Opin. 1996;13(8):465-78. doi: 10.1185/03007999609115227. PubMed 9010613 ↗
  • Ali Algadiem E, Aleisa AA, Alsubaie HI, Buhlaiqah NR, Algadeeb JB, Alsneini HA. Blood Loss Estimation Using Gauze Visual Analogue. Trauma Mon. 2016 May 3;21(2):e34131. doi: 10.5812/traumamon.34131. eCollection 2016 May. PubMed 27626017 ↗
  • Chumlea WC, Roche AF, Steinbaugh ML. Estimating stature from knee height for persons 60 to 90 years of age. J Am Geriatr Soc. 1985 Feb;33(2):116-20. doi: 10.1111/j.1532-5415.1985.tb02276.x. PubMed 3968366 ↗
  • Jiang J, Xing F, Zhe M, Luo R, Xu J, Duan X, Xiang Z. Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials. Front Pharmacol. 2022 Sep 19;13:945971. doi: 10.3389/fphar.2022.945971. eCollection 2022. PubMed 36199695 ↗
  • Masouros P, Antoniou G, Nikolaou VS. Efficacy and safety of tranexamic acid in hip fracture surgery. How does dosage affect outcomes: A meta-analysis of randomized controlled trials. Injury. 2022 Feb;53(2):294-300. doi: 10.1016/j.injury.2021.09.063. Epub 2021 Oct 12. PubMed 34689986 ↗
  • Zhang J, Fan X, Zheng Y, Wu J, Yuan X. Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2023 Jul 27;24(1):614. doi: 10.1186/s12891-023-06725-y. PubMed 37501145 ↗
  • Leverett GD, Marriott A. Intravenous tranexamic acid and thromboembolic events in hip fracture surgery: A systematic review and meta-analysis. Orthop Traumatol Surg Res. 2023 Apr;109(2):103337. doi: 10.1016/j.otsr.2022.103337. Epub 2022 May 25. PubMed 35643364 ↗
  • Augustinus S, Mulders MAM, Gardenbroek TJ, Goslings JC. Tranexamic acid in hip hemiarthroplasty surgery: a systematic review and meta-analysis. Eur J Trauma Emerg Surg. 2023 Jun;49(3):1247-1258. doi: 10.1007/s00068-022-02180-x. Epub 2022 Dec 13. PubMed 36512031 ↗
  • Yang YZ, Cheng QH, Zhang AR, Yang X, Zhang ZZ, Guo HZ. Efficacy and safety of single- and double-dose intravenous tranexamic acid in hip and knee arthroplasty: a systematic review and meta-analysis. J Orthop Surg Res. 2023 Aug 10;18(1):593. doi: 10.1186/s13018-023-03929-9. PubMed 37563702 ↗
  • Zhu J, Zhu Y, Lei P, Zeng M, Su W, Hu Y. Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials. Medicine (Baltimore). 2017 Dec;96(52):e9552. doi: 10.1097/MD.0000000000009552. PubMed 29384974 ↗
  • CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019 Nov 9;394(10210):1713-1723. doi: 10.1016/S0140-6736(19)32233-0. Epub 2019 Oct 14. PubMed 31623894 ↗
  • Smith GH, Tsang J, Molyneux SG, White TO. The hidden blood loss after hip fracture. Injury. 2011 Feb;42(2):133-5. doi: 10.1016/j.injury.2010.02.015. Epub 2010 Mar 16. PubMed 20236640 ↗
  • Zufferey PJ, Miquet M, Quenet S, Martin P, Adam P, Albaladejo P, Mismetti P, Molliex S; tranexamic acid in hip-fracture surgery (THIF) study. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010 Jan;104(1):23-30. doi: 10.1093/bja/aep314. PubMed 19926634 ↗
  • Sing CW, Lin TC, Bartholomew S, Bell JS, Bennett C, Beyene K, Bosco-Levy P, Bradbury BD, Chan AHY, Chandran M, Cooper C, de Ridder M, Doyon CY, Droz-Perroteau C, Ganesan G, Hartikainen S, Ilomaki J, Jeong HE, Kiel DP, Kubota K, Lai EC, Lange JL, Lewiecki EM, Lin J, Liu J, Maskell J, de Abreu MM, O'Kelly J, Ooba N, Pedersen AB, Prats-Uribe A, Prieto-Alhambra D, Qin SX, Shin JY, Sorensen HT, Tan KB, Thomas T, Tolppanen AM, Verhamme KMC, Wang GH, Watcharathanakij S, Wood SJ, Cheung CL, Wong ICK. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality. J Bone Miner Res. 2023 Aug;38(8):1064-1075. doi: 10.1002/jbmr.4821. Epub 2023 May 29. PubMed 37118993 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for May 2027, 15 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 15 months is below that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 25, 2026
StartActual
Feb 17, 2026
Primary completionEst.
May 2027
CompletionEst.
Sep 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07432737
Lead sponsor
University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje
Responsible party
Angelina Krsteva (MD, University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje) — Principal investigator
First posted
Feb 25, 2026
Start date
Feb 17, 2026
Primary completion
May 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Angelina Krsteva, MD
Contact
drangelinakrsteva@yahoo.com
+38971790239

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion